Institute for Research in Molecular Medicine (INFORMM) , Universiti Sains Malaysia , 11800 Minden , Penang , Malaysia.
School of Data Science , Perdana University , 43400 Sri Kembangan , Selangor , Malaysia.
J Chem Inf Model. 2019 May 28;59(5):2487-2495. doi: 10.1021/acs.jcim.8b00963. Epub 2019 Mar 14.
Isocitrate lyase (ICL) is a persistent factor for the survival of dormant stage Mycobacterium tuberculosis (MTB), thus a potential drug target for tuberculosis treatment. In this work, ensemble docking approach was used to screen for potential inhibitors of ICL. The ensemble conformations of ICL active site were obtained from molecular dynamics simulation on three dimer form systems, namely the apo ICL, ICL in complex with metabolites (glyoxylate and succinate), and ICL in complex with substrate (isocitrate). Together with the ensemble conformations and the X-ray crystal structures, 22 structures were used for the screening against Malaysian Natural Compound Database (NADI). The top 10 compounds for each ensemble conformation were selected. The number of compounds was then further narrowed down to 22 compounds that were within the Lipinski's Rule of Five for drug-likeliness and were also docked into more than one ensemble conformation. Theses 22 compounds were furthered evaluate using whole cell assay. Some compounds were not commercially available; therefore, plant crude extracts were used for the whole cell assay. Compared to itaconate (the known inhibitor of ICL), crude extracts from Manilkara zapota, Morinda citrifolia, Vitex negundo, and Momordica charantia showed some inhibition activity. The MIC/MBC value were 12.5/25, 12.5/25, 0.78/1.6, and 0.39/1.6 mg/mL, respectively. This work could serve as a preliminary study in order to narrow the scope for high throughput screening in the future.
异柠檬酸裂解酶(ICL)是休眠期结核分枝杆菌(MTB)存活的持久因素,因此是结核病治疗的潜在药物靶点。在这项工作中,使用集合对接方法筛选 ICL 的潜在抑制剂。通过对三个二聚体系统(即无配体 ICL、与代谢物(乙醛酸和琥珀酸)结合的 ICL 和与底物(异柠檬酸)结合的 ICL)的分子动力学模拟,获得了 ICL 活性位点的集合构象。结合集合构象和 X 射线晶体结构,对马来西亚天然化合物数据库(NADI)进行了 22 种结构的筛选。为每个集合构象选择了前 10 种化合物。然后,将化合物的数量进一步缩小到 22 种符合 Lipinski 五规则(药物似性)且结合到多个集合构象中的化合物。对这些 22 种化合物进行了全细胞测定进一步评估。由于某些化合物无法商业化获得,因此使用植物粗提物进行全细胞测定。与衣康酸(ICL 的已知抑制剂)相比,来自 Manilkara zapota、Morinda citrifolia、Vitex negundo 和 Momordica charantia 的粗提物显示出一些抑制活性。MIC/MBC 值分别为 12.5/25、12.5/25、0.78/1.6 和 0.39/1.6mg/mL。这项工作可以作为未来高通量筛选的初步研究,以缩小范围。